SOURCE: Xtalks

Xtalks Webinars

October 19, 2015 06:30 ET

Precision Medicine: Shifting From One Drug for All Trials to Targeted Therapy Trials, New Webinar Hosted by Xtalks

The Complimentary 1-Hour Broadcast Takes Place on Wednesday, October 28, 2015 at 11am EDT / 3pm GMT

TORONTO, ON--(Marketwired - October 19, 2015) - With the advancements in clinical informatics and genomics over the last decade, there has been a paradigm shift from "one drug fits all" towards personalized medicine across therapeutic areas, known as precision medicine. Precision medicine finds better matches for existing drugs and identifies individuals with best responses, ensuring the right drug finds the right patient at the right time. Using genomic technologies during the preclinical oncology drug development phase facilitates identification of new biomarkers that can be leveraged clinically to optimize precision medicine in clinical trial designs. Precision medicine involves screening patients to identify individuals whose genetic makeup is likely aligned with the molecular mechanisms of a drug, increasing the probability that a patient responds to the therapy. The FDA considers this targeted approach of precision medicine to have manifold benefits, highlight data that provides more information on the safety, efficacy and genetic predispositions that contribute to varied patient outcomes. The FDA has developed guidance on review programs, including the Accelerated Approval Program, which is intended to expedite the approval of targeted therapeutics (based on surrogate endpoints/Biomarkers/Companion Diagnostics), thus ensuring that drugs with well understood response rates are fast-tracked.

The complexity of cancer continues to be appreciated, even as we gain a better understanding of cell signaling pathways and host immune responses. Genetic alterations play a pivotal role in the growth of all types of cancer, and researchers also have found that individual cancer tumors have a unique genetic profile. Analyzing these genetic profiles with NGS aids in understanding the relationship between biomarkers and patient responses. Genomic technologies facilitate the simultaneous measurement of a compendium of oncology markers that can be used in two ways: to match patients to specific drugs, but also to characterize new associations between biomarkers and therapeutics. Translational research is leveraging this knowledge to pave the way for new therapies and improved use of existing therapies.

Expression Analysis (EA), a Q2 Solutions company, has developed a menu of genomic tests to supplement many endpoints for complex clinical trials, including a Comprehensive Cancer Panel (Q2 Solutions CCP), HLA typing, exome sequencing and pan-cancer immune-profiling. These assays can be used singly, to match patient to drug -- including therapeutic benefit as well as lack thereof -- or in combination, to set the stage for more precise and individualized therapeutics, also known as precision medicine. BioPharma can improve the probability of clinical trial success with the QSolutions genomic panels to:

  • Detect the most common actionable somatic alterations currently reported in cancer, including: point mutations, insertions, deletions and structural rearrangements
  • Build comprehensive molecular information on genes of the most well understood pathways, creating a data source that can be used to influence new patient populations likely to benefit from targeted therapies
  • Do more with less material, for reduction in testing turnaround time and overall cost

The featured speakers for this webinar are:

  • Patrice Hugo, Ph.D., Chief Scientific Officer, Q2 Solutions, a Quintiles Quest Joint Venture
  • Victor Weigman, Ph.D., Associate Director, Translational Genomics, Q2 Solutions, a Quintiles Quest Joint Venture

To register or learn more about this complimentary event visit: Precision Medicine: Shifting from One Drug for All Trials to Targeted Therapy Trials

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit

For information about hosting a webinar visit

Image Available:

Contact Information